Overview

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of probiotics, a beneficial intestinal bacteria supplement, if it will cause improvement of the non-alcoholic fatty liver disease (NAFLD) and or non-alcoholic steatohepatitis (NASH- an inflammation with concurrent fatty accumulation of the liver) as measured by transient elastography - an ultrasound of the liver that assess the elastic properties (density) and stiffness of the liver tissue. This study will enroll patients 18 years and older with diagnosis of NAFLD and or NASH.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
William Beaumont Hospitals